CSL (AU:CSL)
ASX:CSL
CSL Stock Chart & Stats
AU$140.99
-AU$0.78(-0.27%)
At close: 4:00 PM EST
AU$140.99
-AU$0.78(-0.27%)
Day’s Range― - ―
52-Week RangeAU$133.35 - AU$275.79
Previous CloseN/A
Volume375.76K
Average Volume (3M)974.43K
Market Cap
AU$68.43B
Enterprise ValueAU$58.72B
Total Cash (Recent Filing)AU$1.15B
Total Debt (Recent Filing)AU$12.58B
Price to Earnings (P/E)34.1
Beta0.59
Next Earnings
Aug 18, 2026EPS Estimate
4.05Next Dividend Ex-DateN/A
Dividend Yield2.58%
Share Statistics
EPS (TTM)5.77
Shares Outstanding485,318,970
10 Day Avg. Volume1,091,561
30 Day Avg. Volume974,433
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)3.94
Price to Sales (P/S)4.94
P/FCF Ratio29.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$217.81Price Target Upside54.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)6.9
Revenue Forecast (FY)AU$15.78B
Bulls Say, Bears Say
Bulls Say
Cash Generation And ConversionSustained free cash flow growth (25.2%) and an operating cash flow to net income ratio of 1.19 show durable cash conversion. This underpins funding for R&D, buybacks and restructuring while providing financial flexibility to absorb cyclical setbacks and support long-term investment priorities.
High Profit Margins And Operating EfficiencyRobust gross and net margins and healthy EBIT reflect structural advantages in biologics manufacturing and pricing power for specialty therapies. Strong margins support reinvestment and resilience to cost pressures, helping sustain earnings through product cycles and policy shifts over months to years.
New Product Momentum And Vaccine Commercial StrengthGrowing uptake of recently launched therapies and differentiated vaccine franchises shows durable commercial execution and pipeline payoff. Adoption of premium products can shift mix toward higher-margin sales, partially offsetting legacy headwinds and supporting medium-term revenue recovery if launches continue to scale.
Bears Say
Large Impairments And Restructuring CostsSignificant non-cash impairments and substantial restructuring charges highlight past allocation or program failures and impose near-term earnings volatility. Even if largely non-cash, these write-downs reduce reported capitalized assets and raise execution risk for returning to prior growth trajectories.
Recent Revenue Decline And Portfolio HeadwindsA falling top line and weaker underlying earnings, driven by Ig portfolio setbacks and policy impacts, signal structural revenue sensitivity to reimbursement and contract timing. Sustained recovery depends on execution in key franchises and favorable policy or tender outcomes over the coming quarters.
Competition, Loss Of Exclusivity And Policy ExposureMaterial exposure to generic competition, impending loss of exclusivity and low‑priced competitors create durable downside to certain product cash flows. These structural threats can depress margins and volume in affected franchises and require successful new-product uptake to fully offset lost revenue streams.
CSL News
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$133.35 and its highest was AU$275.79 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is AU$68.43B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Aug 18, 2026 which is in 144 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Feb 10, 2026. The company reported AU$5.773 earnings per share for the quarter, missing the consensus estimate of AU$5.93 by -AU$0.158.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$2.451 which represents an annual dividend yield of 2.58%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 4.05.
How many shares outstanding does CSL have?
CSL has 485,318,970 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$5.773 in its last earnings report, missing expectations of AU$5.93. Following the earnings report the stock price went down -4.638%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$217.81 (54.49% Upside)
AU$217.81 (54.49% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 86%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 78%
Bearish news 22%
Bearish news 22%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSL Company Deck
CSL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: operational strengths (strong cash generation, share buyback expansion, cost-savings progress, solid Vifor performance, successful new product launches and Seqirus commercial gains) are offset by meaningful near-term pressures (H1 revenue decline, major non-cash impairments and one-off restructuring costs, policy-driven weakness in albumin and Ig headwinds, iron generics and KCENTRA competitive pricing). Management emphasizes these impairments are largely non‑cash, that the transformation is delivering tangible savings, and they have maintained full-year guidance while laying out remediation steps for weaker areas. The tone is cautiously constructive but with material near-term risks that require execution in H2 to validate the outlook.View all AU:CSL earnings summariesCSL Stock 12 Month Forecast
Average Price Target
AU$217.81
▲(54.49% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Options Prices
Currently, No data available
---